A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy Clinical Trial

Official title:

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO -CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF 06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING IN HEALTHY ADULT MALE PARTICIPANTS AND OPEN-LABEL AFTER SINGLE SUBCUTANEOUS DOSING IN MALE AND FEMALE PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03275740
• Other study ID #: B7801001
• Secondary ID: 2018-003315-21
• Status: Terminated
• Phase: Phase 1
• Start date: July 17, 2017
• Est. completion date: January 6, 2023

Study information

• Verified date: May 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP). Pharmacokinetics and pharmacodynamics will also be evaluated.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 58
• Est. completion date: January 6, 2023
• Est. primary completion date: January 6, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria Healthy male participants:

• at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including oral temperature, blood pressure (BP) and pulse rate measurement, pulse oximetry, 12 lead ECG or clinical laboratory tests.
• Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
• Chest X ray with no evidence of current, active tuberculosis (TB) or previous inactive TB, general infections, heart failure, malignancy, or other clinically significant abnormalities taken at Screening or within 3 months prior to Screening and read by a qualified radiologist.

Exclusion Criteria for Healthy male participants:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Participants with a history of autoimmune disorders and other conditions that compromise or impair the immune system (including but not limited to: Crohns Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves disease, and asthma) or have a current positive result for the following; rheumatoid factor, anti-nuclear antibody, or abnormal free triiodothyronine (T3), free thyroxine (T4), thyroid stimulating hormone (TSH), or thyroid stimulating antibody (TSAb) suggestive of thyroid disease.
• Subjects with a history of allergic or anaphylactic reaction to any drug including immunoglobulin.
• History of active infections within 28 days prior to the screening visit.
• Subjects with a history of or current positive results for any of the following serological tests: Hepatitis B surface antigen (HepBsAg), Hepatitis B core antibody (HepBcAb), Hepatitis C antibody (HCVAb) or human immunodeficiency virus (HIV).
• Subjects with a history of thromboembolic events.
• History of TB or active, latent or inadequately treated TB infection. All positive TB test result(s) are exclusionary
• Male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study.
• Inclusion Criteria for ITP participants:

Female participants may be of childbearing potential or non-childbearing potential. -Diagnosis of Primary ITP. ITP must be diagnosed in accordance with established guidelines. ITP duration-Persistent (>3 months and =12 months) OR Chronic (>12 months). AND

• Platelet count 30-75 x 10E9/L (inclusive) with criteria achieved on 2 qualifying counts at least 5 days apart and within approx. 10 days of dosing
• Participants must have received and responded to IVIg or corticosteroids as treatment for ITP (response is defined as achievement of platelet count >50 x 109/L and doubling of platelet count from baseline). --Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
• BMI of 17.5 to 30.5 kg/m2 and a total body weight >40 kg (88 lbs). Exclusion Criteria for ITP participants
• History of clinically significant hematological (other than ITP), renal, endocrine, metabolic, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Chest X-ray with evidence of current, active TB, previous inactive TB, general infections, heart failure, malignancy, or other clinically significant abnormalities. Chest x-ray must be taken at Screening or within 3 months prior to Screening and read by a qualified radiologist.
• Any bleeding event requiring medical evaluation or treatment in the 4 weeks prior to screening or current bleeding event that requires treatment.
• Scheduled or anticipated invasive procedures (eg, surgery, dental procedures) within 28 days following PF-06755347 dosing.
• Splenectomy within =180 days prior to PF-06755347 dosing or splenectomy planned during the period of the study.
• History of any active autoimmune disorder (other than ITP) or other conditions that may compromise or impair the immune system (including but not limited to: Crohn's Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves' disease, and asthma).
• History of allergic or anaphylactic reaction to any drug including immunoglobulin.
• History of active infections within 28 days prior to the screening visit.
• History of Hepatitis B, Hepatitis C or HIV or current positive results for any of the following serological tests - HBsAg, HBcAb, HCVAb or HIV.
• History of thromboembolic events
• Hemoglobin <9 g/dL.
• Positive Direct Coombs test

Related Conditions & MeSH terms

• Healthy
• Polyradiculoneuropathy
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
• Primary Immune Thrombocytopenia
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• PF-06755347 intravenous healthy participant
Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
• Placebo intravenous healthy participant
Placebo comparator
• PF-06755347 subcutaneous healthy participant
single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
• Placebo subcutaneous healthy participant
placebo comparator
• PF-06755347 subcutaneous ITP
single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants

Locations

Country	Name	City	State
Belgium	Pfizer Clinical Research Unit	Brussels
New Zealand	NZCR (New Zealand Clinical Research) OPCO Limited	Christchurch
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Virgen del Rocío	Sevilla
United Kingdom	Hammersmith Medicines Research (HMR)	London
United States	Pfizer New Haven Clinical Research Unit	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Belgium,  New Zealand,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)		Baseline (study day -2) through study completion (study day 36 for intravenous dose cohorts 1 - 6, and study day 71 for subcutaneous dose cohorts.
Primary	Number of Participants With Clinical Laboratory Abnormalities	Safety laboratory includes Hematology, Chemistry, Urinalysis, prothrombin time/international normalized ratio, partial thromboplastin time, D dimer, and fibrinogen	Baseline, study days 1, 2, 4, 6, 8, 11, 15, 22, 29 and 36 for i.v. dose cohorts 1 - 6, and Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for subcutaneous dose cohorts.
Primary	Number of Participants With Categorical Vital Signs Data	Vital signs include blood pressure, pulse rate, and body temperature. Number of participants with maximum increase from Baseline in sitting SBP and DBP of greater than or equal to 30 mmHg will be reported	Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, and day 36 for i.v. dose cohorts 1 - 6 and Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for subcutaneous dose cohorts.
Primary	Number of Participants With Abnormal Electrocardiogram (ECG)	Criteria for ECG abnormalities: maximum PR interval >=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) >=25 percent (%) for baseline value of >200 msec and Pctchg>=50% for baseline value of <=200 msec for PR interval, maximum QRS interval >=140 msec and a maximum IFB: Pctchg>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to <480 msec, 480 msec to <500 msec or >=500 msec and a maximum change of <=30change<60 or >=60 msec from baseline.	Baseline (study day 1, pre-dose), study days 1 (post dose), 2, 4, 6, 8, 11, 22, 36 (end of study visit for intravenous dose cohorts 1 - 6, and end of study visit day 71) for subcutaneous dose cohorts.
Secondary	Maximum Observed Plasma Concentration (Cmax)		Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Dose Normalized Maximum Observed Plasma Concentration Cmax		Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Time to Reach Maximum Observed Plasma Concentration (Tmax)		Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)	Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)	Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)		Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)	AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).	Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)		Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Plasma Decay Half-Life (t1/2)	Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.	Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Apparent Clearance (CL)	Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of study drug (R0/Css)	Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary	Incidence of Anti-Drug Antibody (ADA)		Baseline, study days 8, 15, and 36 for all dose cohorts plus day 71 for subcu cohorts
Secondary	Characterization of biomarker changes		Day -1, hours 0, 5, 12, 24, 48, 72 for all cohorts. Hours 1 (or end of infusion, 8, 120 and days 11 & 29 for i.v. cohorts Days 5, 8, 15, 36 & 71 for subcutaneous cohorts.

External Links

•   To obtain contact information for a study center near you, click here.